After years of talks, Korea's Celltrion Group is finally moving ahead with the merger of three key affiliates aimed at improving cost competitiveness and securing investment resources, as well as simplifying transaction structures and improving governance.

After years of talks, Korea's Celltrion Group is finally moving ahead with the merger of three key affiliates aimed at improving cost competitiveness and securing investment resources, as well as simplifying transaction structures and improving governance.

As Stelara biosimilars wait in the wings, proposed legislation in the US could ease the path to commercialization. The Draft Red Tape Elimination Act aims to remove a requirement for switching studies. Opposition to the bill is expected, but if passed how much will the Act move the biosimilars needle in the country?

Public Company Edition: UroGen raised $120m in a private placement of ordinary shares. Also, Verrica entered into a debt financing for up to $125m upon approval of Ycanth for molluscum contagiosum and job cuts were announced by Homology, Mersana, Infinity and others.